Working with your broader project team, XenoGesis provides guidance throughout the lifetime of your project through our consultancy support.
Areas of expertise include:
- Defining early discovery screening cascades, interpretation of in vitro data and recommendations for progression to in vivo studies
- PK and PK-PD modelling and simulation including recommendations of dose selection and frequency for PD studies
- Prediction of human PK using allometric and physiologically based pharmacokinetic (PBPK) approaches
- Prediction of efficacious human dose (integrating human PK prediction with PK-PD hypothesis)
- Assessment of drug-drug interaction risks (CYPs and transporters)
- Due diligence (in-licensing evaluation or out-licensing support)